Biogen (BIIB) Gains 5% on Strong Q4 Results, Promising Outlook

Go back to Biogen (BIIB) Gains 5% on Strong Q4 Results, Promising Outlook

Biogen 2015 Revenues Increase 11% to $10.8 Billion

January 27, 2016 7:15 AM EST

2015 Non-GAAP Diluted EPS Rise 23%, GAAP Diluted EPS Rise 24%

Company advances leading neuroscience portfolio including programs in Alzheimers disease, spinal muscular atrophy, and a repair & regeneration therapy for multiple sclerosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported full year and fourth quarter 2015 results, including full year revenues of $10.8 billion, an 11% increase versus 2014. Full year 2015 Non-GAAP diluted earnings per share (EPS) were $17.01, an increase of 23% versus 2014. Non-GAAP net income attributable to Biogen Inc. for the year was $3.9 billion, an increase of 20% versus the prior... More